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Abstract
Background. In the Irbesartan in Diabetic Nephro-
pathy Trial (IDNT), treatment with irbesartan demon-
strated 23 and 20% reductions in the combined
endpoint of doubling of serum creatinine (DSC), end-
stage renal disease (ESRD) or death in patients with
hypertension, type 2 diabetes and overt nephropathy
compared with amlodipine and control, respectively. A
simulation model was developed to project long-term
cost consequences of the IDNT in Belgium and France.
Methods. A Markov model simulated progression
from nephropathy to DSC, ESRD and death in
patients with hypertension, type 2 diabetes and overt
nephropathy. Treatment-speciﬁc probabilities were
derived from IDNT. Country-speciﬁc ESRD-related
data were retrieved from published sources. Delay in
onset of ESRD, life expectancy and mean lifetime costs
were calculated for patients with a baseline age of 59
years. Future costs were discounted at 3% per annum
(p.a.), and clinical beneﬁts were discounted at 0 and 3%
p.a.. Extensive sensitivity analyses were performed.
Results. Onset of ESRD was delayed with irbesartan
by 1.41 and 1.35 years vs amlodipine and control,
respectively. When a 10-year time horizon was con-
sidered, delay in ESRD onset led to anticipated im-
provements in life expectancy of 0.13 years vs
amlodipine and 0.26 years vs control. Irbesartan was
associated with cost savings of “14 949 and
“9205/patient in Belgium, and “20 128 and “13 337
in France, vs amlodipine and control, respectively. The
results were robust under a wide range of plausible
assumptions.
Conclusions. Treating patients with hypertension,
type 2 diabetes and overt nephropathy using irbesartan
was both cost- and life-saving compared with
amlodipine and control.
Keywords: amlodipine; hypertension; irbesartan;
nephropathy; type 2 diabetes
Introduction
There has been an explosive increase in the incidence
and prevalence of end-stage renal disease (ESRD) with
type 2 diabetes as the major underlying cause over the
last decade in the western world [1]. Between 1993 and
1999 there was an annual increase of 5% in the
prevalence of ESRD in France [1]. With the prevalence
of diabetes among renal replacement therapy patients
21% the scale of this problem is clear. Moreover,
renal replacement therapy patients with type 2 diabetes
have high morbidity and mortality rates. In France, the
median survival time is 2.7 years and cardiovascular
mortality the main cause of death [2].
TheIrbesartaninDiabeticNephropathyTrial (IDNT)
was a multicentre, double-blind, placebo controlled
study assessing the effect of irbesartan (angiotensin II-
receptor blocker) vs amlodipine (dihydropyridine
calcium channel blocker) or placebo on the progression
of diabetic renal disease and all-cause mortality in
hypertensive patients with type 2 diabetes and protei-
nuria [3]. Irbesartan treatment resulted in a reduction of
23% in the combined endpoint of death, ESRD and
doubling of serum creatinine (DSC) compared with
amlodipine (P¼ 0.006) and a 20% reduction compared
with the control group (P¼ 0.02). We developed a
Correspondence and offprint requests to: Dr Andrew J. Palmer,
CORE – Center for Outcomes Research, St Johanns-Ring 139,
CH-4056 Basel, Switzerland. Email: ap@thecenter.ch
 2003 European Renal Association–European Dialysis and Transplant Association
Markov model (a common approach to simulate long-
termprogressive diseases [4]) to extrapolate the results of
the IDNT and project long-term clinical and cost
outcomes. This article provides a description of the
methodology used and reports the ﬁndings of this long-
term simulation.While other treatment agents like ACE
inhibitors are also used in this patient group, and health-
economic comparisons with ACE inhibitors and other
medications would be interesting if appropriate clinical
data were available, we restricted the analysis to the
treatments assessed in the IDNT due to lack of direct
clinical comparisons between angiotensin II-receptor
blockers and ACE inhibitors.
Subjects and methods
Model structure
A computer-based Markov simulation software program was
developed to model the clinical course of disease of a
population with type 2 diabetes, overt nephropathy and
hypertension as they progressed to DSC, onset of ESRD
(treated with either dialysis or renal transplantation) and
death. Markov models are made up of a set of distinct states,
with transitions between the states occurring according to
probabilities, which are usually derived from published
studies. When a simulation is run, simulated patients can
remain in any particular state or switch to another state in
each cycle of the simulation (usually representing 1 year) until
they reach a terminal state (for example death) or the time
horizon is reached.
In this analysis, the model consisted of ﬁve primary
health states (Figure 1), with all patients starting in the ‘no
progression’ state:
(i) Initial or ‘no progression state’: IDNT patient at
inclusion with type 2 diabetes and proteinuria
(900mg/24 h).
(ii) Progression of diabetic nephropathy with DSC.
(iii) ESRD treated with dialysis.
(iv) ESRD receiving transplant.
(v) Death.
Cohort and treatment groups
The model simulated a hypothetical cohort of patients with
type 2 diabetic nephropathy similar to those in the IDNT. The
baseline characteristics of this cohort have been described
previously [5]. Three treatment choices were simulated based
on treatments in the IDNT: irbesartan titrated from 75 to
300mg/day, amlodipine titrated from 2.5 to 10mg/day, or
control (standard antihypertensive therapy, excluding ACE
inhibitors, angiotensin-receptor blockers or calcium channel
blockers). Other antihypertensive drugs were permitted to
achieve target blood pressure (135/85 mmHg).
Clinical data inputs (transition probabilities)
Probabilities from the states ‘no progression’ and ‘DSC’ are
summarized in Table 1. The duration of the IDNT was up
to 5 years with 2.9 years as the mean length of total patient
follow up. Transitional probabilities for the ﬁrst 3 years of
the model were obtained from the actual number of annual
events in the IDNT clinical trial. For the remainder of the
model, an average of probabilities across those ﬁrst 3 years
was used for each arm.
Once a patient progressed to the ‘DSC’ state, the
transition probability to ESRD increased in comparison
with the ‘no progression’ state. Rodby et al. [6] showed that
the median time from DSC to ESRD, based on IDNT data,
varied between treatment arms: 328 days with irbesartan,
301 days with amlodipine and 273 days with control. The
data, together with an assumption of a constant hazard rate
function, were applied to estimate the annual probability of
transition from DSC to ESRD in each treatment arm.
Table 1. Overview of probabilities derived from the IDNT
Year Probability
Irbesartan Amlodipine Control
Probability of moving from ‘no progression’ to ‘DSC’
1 0.0069 0.0141 0.0141
2 0.0454 0.0507 0.0486
3 0.0423 0.0872 0.0644
4þ 0.0315 0.0507 0.0424
Probability of moving from ‘no progression’ to ‘ESRD’
1 0.0311 0.0264 0.0246
2 0.0207 0.0487 0.0447
3 0.0249 0.0410 0.0396
4þ 0.0256 0.0388 0.0363
Probability of moving from ‘DSC’ to ‘ESRD’
1þ 0.537606 0.568517 0.604156
Probabilities were calculated from the following sample sizes (ﬁrst,
second and third years, respectively) for irbesartan: 579, 529 and
430 patients; for amlodipine: 567, 513 and 390 patients; and for the
control group: 569, 514 and 404 patients. For year 4 and beyond,
the average of the ﬁrst 3 years was used for each treatment arm.
Probability¼ annual transition probability; ‘year’ refers to year of
model simulation. Distinction was made between the Belgian and
French probabilities of transplantation and dialysis due to
differences in country-speciﬁc ESRD management practices.
Fig. 1. The simulated cohort started in the ‘no progression’ state.
Patients may remain in a given state, or progress to another state.
The state of ‘no progression’ represents the cohort state at the start
of the IDNT.
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Mortality rates for patients in the ‘no progression’ and
‘DSC’ states were assumed to be equal as there is no evidence
that patients with DSC (and not progressing to ESRD) have a
higher mortality rate than those without DSC. To calculate
the annual probabilities of dying, the mean annual death rates
in each treatment arm over the 2.9-year follow up period were
converted to transition probabilities using the ‘RatetoProb’
function of the DATA software. For the ﬁrst 10 years of the
model, mortality data from the IDNT were used [3].
Age was taken into account from year 10, based on the
published evidence that mortality doubles every 10 years in
type 2 diabetes patients [7]. Mortality was age-adjusted by
doubling it with every 10-year increase in age (after the ﬁrst
10 years of simulation).
When a simulated patient developed ESRD, the prob-
abilities of death or changing between the dialysis and renal
transplant states were assumed to be independent of treat-
ment arm. The model outcome was adapted to the French and
Belgian settings by incorporation of country-speciﬁc ESRD
management and outcomes data for Belgium and France
where available (Table 2) [8–10]. There were two main
exceptions to this:
(i) In Belgium, the transition from transplant to dialysis was
high in the ﬁrst year but much lower in subsequent years
[8]. For France, the transitions from dialysis to
transplant and from transplant to dialysis (transplant
failure) were only available for 1 year. Therefore, the
Belgian data were used as a proxy for these transitions
for all subsequent years in France.
(ii) Reliable mortality rates for patients receiving renal
transplants were not found for either France or
Belgium. It was assumed that mortality rates would
not differ widely in Western countries, and US ﬁgures
for transplant patients (not speciﬁc to gender or race)
were applied [10].
Cost inputs
The perspective of a third party payer [i.e. social security in
France, Institut National d’Assurance de Maladie et
Invalidite´ (INAMI) in Belgium] was taken. Costs of
medications and ESRD were assessed for patients in all
three treatment arms. Costs of cardiovascular events and
management (e.g. visits to the general practitioner, urinary
albumin monitoring and other investigations that were
similar in each treatment arm) were not considered, as we
wanted to determine the incremental costs between each
treatment arm. Therefore, costs for patients in the states ‘no
progression’ and ‘DSC’ were based on study drugs and
concomitant antihypertensive agents, and for patients in with
ESRD costs of dialysis or transplant were also included.
To determine study drug medication costs (irbesartan
75, 100 and 300 mg, and amlodipine 2.5, 5 and 10 mg),
exposure time by dose was calculated for all patients in the
IDNT study. The cost of each dose was calculated from the
INAMI tariffs for Belgium and the VIDAL database for
France. The cost of study medication was calculated by
dividing the number of days exposed to each dose by the
number of patients, multiplied by the mean duration of
follow up, multiplied by the cost of that dose (Table 3).
The average annual costs of concomitant medications
(Table 3) were based on the same sources. Exposure to
antihypertensive medication classes and adjunctive hyper-
tensive medications was calculated for each treatment arm.
For each therapeutic class, the price of the drug which is
currently most used was utilized.
Cost estimates for transplant or dialysis due to ESRD
were based on total third party reimbursement (Table 4)
[8,11–15]. Cost ﬁgures speciﬁc to ESRD of diabetic
aetiology (or better still, type 2 diabetes aetiology) were
not available for Belgium. However, Lins has reported full
annual costs of managing patients with ESRD in Belgium
based on reports from nephrology centres, which were used
for this analysis [8,12]. These ﬁgures related to all patients
treated with renal replacement therapy. Cost estimates for
France were derived from several sources. Jungers et al. [11]
reported the following distribution of dialysis patients for
Ile-de-France: 68.3% in-centre; 31.7% out-centre (self-care
haemodialysis 18.5%, home haemodialysis 1.7%, or
peritoneal dialysis 11.6%). Engel et al. [14] published the
speciﬁc cost of diabetic ESRD patients. Taking into account
the relative weights of the different types of dialysis [11], a
cost of “56 768 per year was estimated. Average length of
hospital stay was estimated to be 13.4 days at a cost per day
of “327.72 [15,16]. Taking the cost of hospitalization into
account, the total cost for dialysis in France was “61 159.
These ﬁgures relate to diabetes patients (not subdivided by
Table 2. Country-speciﬁc transition probabilities from ESRD states
Belgium France
Year Probability Year Probability
Probability of moving from ‘dialysis’ to ‘transplant’
1 0.0460 1 0.0415
2 0.0340 2 0.0415
3 0.0230 3 0.0415
4 0.0130 4 0.0415
5þ 0.0080 5þ 0.0415
Probability of moving from ‘transplant’ to ‘dialysis’
1 0.1000 1 0.1000
2þ 0.0193 2þ 0.0193
Probability of moving from ‘dialysis’ to ‘death’
1þ 0.1897 1þ 0.1937
Probability of moving from ‘transplant’ to ‘death’
1 0.0737 1 0.0737
2–6 0.0932 2–6 0.0932
7–11 0.1140 7–11 0.1140
12–21 0.1664 12–21 0.1664
22þ 0.1876 22þ 0.1876
Probability, annual transition probability; ‘year’ refers to year of
model simulation; distinction was made between the Belgian and
French probabilities of transplantation and dialysis due to differ-
ences in country-speciﬁc ESRD management practices.
Table 3. Country-speciﬁc parameters used to calculate the costs of
treatment and other management costs for each treatment arm
Annual costs of medications Belgium
(“ per year)
France
(“ per year)
Irbesartan costs 353.66 232.50
Irbesartan concomitant medications 140.35 123.21
Amlodipine costs 243.43 204.09
Amlodipine concomitant medications 136.07 120.77
Control costs – –
Control concomitant medications 153.12 135.60
Health economics of irbesartan in Belgium and France 2061
type of diabetes); Cogny et al. [13] described transplantation
costs for a single centre in France. Costs of transplantation
in the ﬁrst, second and third years were calculated to be
“19 026, “6306 and “5309, respectively. These costs did not
include the costs of more recent immunosuppressive therapy
like tacrolimus. The addition of tacrolimus to the immuno-
suppressive regimen may not necessarily increase the total
costs associated with transplantation, as the acquisition
costs of the medications are offset by reductions in hos-
pitalizations and rejections. It is therefore unclear if the
exclusion of tacrolimus from the cost analysis following
transplantation leads to an under- or over-estimation of
the total costs following transplantation [17]. Costs were
converted to 2002 values based on a 3% annual actual-
ization rate.
Discounting
Discounting is the process by which the future costs and/or
beneﬁts (beyond 12 months) are converted to equivalent
present values. Discounting is commonly used in health
economic analyses to adjust for the diminished value of
future costs and beneﬁts. The reasons for discounting are
the time preference (costs and beneﬁts in the future are not
as highly valued as costs or beneﬁts that can be realized
immediately) and other diseases or medical advances may
intervene, thereby fully or partially negating the expected
future beneﬁts of any given intervention. In the present
study, future costs and future clinical beneﬁts where
discounted at a rate of 3% per annum (p.a.) [4].
Sensitivity analysis
One-way sensitivity analyses were performed on total costs
and life expectancy to assess the impact of different
assumptions on the results. The impact of discount rates for
costs and life expectancy was evaluated by varying discount
rates between 0 and 6%. Sensitivity analysis was performed
on the extrapolation of transition probabilities beyond the
3-year trial period. In the base case analysis, transitional
probabilities for the ﬁrst 3 years of the model were obtained
from the actual number of annual events in the IDNT
clinical trial. For the remainder of the model, an average of
probabilities across those ﬁrst 3 years for each treatment
arm was used. As an extremely conservative assumption for
sensitivity analysis, it was assumed that the probabilities
would return to those of the control group after the 3-year
trial period in all treatment arms (i.e. only the within-trial
effects of irbesartan and amlodipine were considered).
Results
Irbesartan was associated with delayed onset of ESRD
compared with amlodipine and control. Mean time to
development of ESRD in the irbesartan-treated cohort
was 8.23 years, compared with 6.82 years for
amlodipine and 6.88 for control, corresponding to
delays of 1.41 (vs amlodipine) and 1.35 years (vs
control). Moreover, simulated long-term treatment
with irbesartan was associated with a lower incidence
of ESRD than amlodipine or placebo. At 10 years, the
cumulative incidence of ESRD was 36, 49 and 45% in
the irbesartan, amlodipine and control treatment
arms, respectively. The 25-year (lifetime) cumulative
incidence of ESRD was 47% in the irbesartan
cohort, compared with 59% with amlodipine and 55%
with control. This corresponds to lifetime reductions
in the cumulative incidence of ESRD with irbesartan of
12 and 8% vs amlodipine and control, respectively
(Figure 2).
Life expectancy and total lifetime costs
Both life expectancy and total lifetime costs differed
between the Belgian and French settings due to
different dialysis and transplant rates, survival rates
following the onset of ESRD, and unit costs.
In the Belgian setting life expectancy was improved in
the irbesartan group compared with the amlodipine and
control groups, as anticipated from the delayed onset of
ESRD. Non-discounted life expectancy (discounted at
3% p.a. shown in brackets) was 10.59 (8.57) years with
irbesartan, 9.88 (8.11) years with amlodipine and 9.68
(7.95) years in the control group. This corresponds to
improvements with irbesartan of 0.71 (0.46) years
vs amlodipine and 0.91 (0.62) years vs control. When a
10-year time horizon was used, improvements in
undiscounted life expectancy (discounted shown in
brackets) with irbesartan were 0.13 (0.10) and 0.26
(0.22) years vs amlodipine and control, respectively. In
addition, total lifetime costs were lower in the irbesartan
cohort than in the other treatment groups. Total lifetime
costs (discounted 3%p.a.) were“76 777with irbesartan,
“97 940 with amlodipine and “88 662 with control
(cost savings of “21 163 and “11 885 for irbesartan vs
amlodipine and control, respectively). After 10 years,
cost savings of “14 949 and “9205 vs amlodipine and
control, respectively, were projected (Figure 3).
A similar pattern of results was observed in the
French setting. Life expectancy (discounted at 3%
shown in brackets) was improved with irbesartan
compared with amlodipine or control, with values of
10.61 (8.58) years in the irbesartan group, 9.92 (8.13)
years in the amlodipine group and 9.71 (7.97) years in
Table 4. Country-speciﬁc total costs for end-stage renal disease
treatment
Treatment Annual costs (“) Reference
Year 1 Years 2þ
Belgium
Kidney transplant 21 647 2959 [8,12]
Dialysis 44 638 44 520 [8,12]
France
Kidney transplant 24 102 6725 [13]
Dialysis 61 159 61 159 [14–16]
Costs given include cost of dialysis/transplants and cost of hospital-
izations for comorbidities and complications.
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Fig. 3. Graphs show the cost savings per patient over time for irbesartan compared with amlodipine or control in the Belgian setting (A), or
the French setting (B). In both settings, cost savings become evident after 3 years of treatment with irbesartan. Eighty per cent of the total cost
savings were achieved after 9–11 years of therapy. IRB, irbesartan; AML, amlodipine.
Fig. 2. The cumulative incidence of ESRD after 25 years was 44.7, 57.1 and 52.9% for irbesartan, amlodipine and control, respectively. AML,
amlodipine; IRB, irbesartan.
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the control group. This translated into improvements
of 0.69 (0.45) and 0.90 (0.61) years vs amlodipine
and control, respectively. Ten-year differences in life
expectancy were similar in the French and Belgian
settings. Irbesartan also proved to be cost saving in
the French setting. Total lifetime costs were “93 240
with irbesartan, “120 284 with amlodipine and
“109 585 in the control group, which corresponds to
cost savings of “27 044 and “16 345 for irbesartan vs
amlodipine and control, respectively. Again, impor-
tant cost savings in the irbesartan treatment arm were
observed after 10 years in the French setting (“20 128
vs amlodipine and “13 337 vs control).
Breakdown of the per patient costs revealed that
the cost of irbesartan and amlodipine made up 2–4%
of the total costs considered in this analysis, whereas
ESRD costs contributed to 94–99%. Reduction in
ESRD costs in the irbesartan treatment arm was one
of the major factors that led to overall cost savings in
the irbesartan treatment arm (Table 5). The cost
savings were due mainly to ESRD avoided with
irbesartan and became evident after 3 years of
treatment. In the Belgian setting, after only 5 years,
costs savings were “5180 and “2973 vs amlodipine
and control, respectively. In the French setting after 5
years, cost savings were “7557 and “5058 vs
amlodipine and control, respectively. Eighty per cent
of the overall savings were achieved within 9–11 years
of treatment (Figure 3).
Sensitivity analysis
Using different combinations of discount rates for
costs and clinical outcomes had no impact on the
relative outcomes, with irbesartan remaining both life
and cost saving under all combinations of discount
rates (discount rates from 0 to 6% on costs and
clinical beneﬁts).
The parameter with the greatest single impact on
life expectancy was the annual probability of death in
the state ‘no progression’ (taken from the IDNT),
closely followed by the annual probability of death in
the state ‘ESRD treated with dialysis’ (taken from
country-speciﬁc published sources). It was calculated
that irbesartan would remain life saving compared
with amlodipine with up to a 14% increase in the
probability of dying in the ‘no progression’ state in
the irbesartan treatment arm. In comparison with
placebo, irbesartan remained life saving with up to a
21% increase in this probability.
The parameter with the greatest single impact on
total lifetime costs was the annual costs of dialysis. In
the unlikely case that the costs of dialysis in Belgium
fell below “3220 (compared with “44 580 used in the
base case analysis), irbesartan would no longer be
cost saving compared with amlodipine. The annual
cost of irbesartan had the fourth greatest impact on
total lifetime costs. The annual cost of irbesartan
treatment would have to be higher than “1680 per
patient (compared with the current cost of “353.66)
to lead to an overall cost increase compared with no
treatment (or “2764 compared with amlodipine).
Under the conservative assumption that only the
within-trial (ﬁrst 3 years) effects of irbesartan and
amlodipine were considered (after which transition
probabilities corresponded to those of the control arm),
non-discounted life expectancies (discounted at 3%
shown in brackets) in the Belgian setting were 9.98
(8.17) years for irbesartan, 9.76 (8.02) years for
amlodipine and 9.68 (7.95) years for the control arm.
Total lifetime costs were “88 213 in the irbesartan
group, “93 697 for amlodipine and “88 662 in the
control group. Thus, even with very conservative
assumptions about the long-term effectiveness of
the medications, irbesartan remained both cost and
life saving compared with amlodipine and control.
Discussion
Patients with hypertension, type 2 diabetes and overt
nephropathy are at extremely high risk of developing
ESRD, which is associated with high morbidity,
mortality and treatment costs. Any intervention that
can reduce or delay the progression from nephro-
pathy to ESRD is likely to have a large impact on
cost and clinical outcomes in this patient group.
This is conﬁrmed by the present modelling study,
which demonstrated that a reduction in progression to
DSC and ESRD associated with irbesartan treatment
leads to an important improvement in life expectancy
and reduction in total lifetime costs of medications and
ESRD per patient compared with treatment with
amlodipine or control. The anticipated gains in non-
discounted life expectancy (due to delay in the onset of
ESRD) compare very well with other established
interventions in health care [18]. Cost savings
with irbesartan treatment instead of amlodipine or
standard blood pressure control alone begin to occur
after 3 years of therapy (the within-trial period of the
analysis).
Table 5. Breakdown of mean total lifetime costs per patient
Mean total lifetime costs per patient (“)
Irbesartan Amlodipine Control
Belgium
Total 76 777 (100%) 97 940 (100%) 88 662 (100%)
Drug costs 3029 (4%) 1974 (2%) 0
Adjuvant
medications
1202 (2%) 1103 (1%) 1218 (1%)
ESRD 72546 (94%) 94 863 (97%) 87 444 (99%)
France
Total 93 204 (100%) 120 284 (100%) 109 585 (100%)
Drug costs 1995 (2%) 1659 (1%) 0
Adjuvant
medications
1057 (1%) 982 (1%) 1081 (1%)
ESRD 90188 (97%) 117 643 (98%) 108 504 (99%)
Drug costs, medication costs speciﬁc to treatment arm; %, percent-
age of total costs. The costs associated with dying in the ESRD
states were included in the ESRD costs.
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The results of the model were robust under a wide
range of plausible assumptions about the long-term
effectiveness of drug therapy and costs of complications
and medications, even in the extreme case assuming no
effect of irbesartan or amlodipine after the 3-year trial
period. This sensitivity analysis indicates that the
conclusion of the study would probably not change in a
real-life setting, even taking into account the difference
between efﬁcacy in the clinical trial situation (as in the
IDNT) and real-life effectiveness.
There were some limitations in this modelling study.
Data derived from the IDNT were applied whenever
possible in the model. Some of these probabilities,
although different within treatment arms, were not
statistically signiﬁcant. This is often the case when a
clinical trial is used as a basis for an economic analysis,
as the trial is powered to show a difference only in the
primary endpoint, which is not the only relevant
endpoint used in an economic analysis. For example,
the probability of death from any cause was not
signiﬁcantly different between treatment arms after the
within-trial follow up period, but the IDNT was not
powered for an analysis of this secondary outcome [5].
However, the signiﬁcant delay in the onset of ESRD
seen with irbesartan during the trial period was
projected to lead to important improvements in life
expectancy, primarily due to avoidance of the excess
mortality associated with the onset of ESRD. The
sensitivity analyses revealed that those probabilities,
which were signiﬁcantly different in the IDNT (for
example progression to DSC) had a large impact on the
outcomes, and variation of these probabilities within
plausible ranges did not alter the relative outcomes. The
mortality probabilities following transplantation were
taken from US ﬁgures, and included racial subgroups
with higher mortality rates. This may have led to a
slight over-estimation of the mortality, although the
impact on the results is minimal due to the low rates of
transplantation in Belgium and France. On the other
hand, we assumed that there was no increase in
mortality when patients progressed to DSC. Because
irbesartan delayed progression to DSC, this may have
led to an under-estimation of the associated improve-
ments in life expectancy.
The ESRD treatment costs used in the model were
not type 2 diabetes-speciﬁc. In the US setting, costs of
renal replacement therapies are typically higher for
diabetes patients than other patients [10]. Additionally,
the costs for transplant maintenance in France were
derived from a period when the use of tacrolimus and
other expensive immunosuppressive agents was not
common. These two factors led to a possible under-
estimation of the costs of renal replacement therapy
compared to the current approach with more expensive
immunosuppressants, in turn leading to an under-
estimation of the cost savings to be expected with
irbesartan.
It should be noted that the population of the IDNT
represented patients with advanced diabetic nephro-
pathy, and as such these results should only be taken
in the context of these patients and not in those with
microalbuminuria. Moreover, the purpose of the
IDNT was to investigate the effects of irbesartan,
amlodipine or placebo on the progression to DSC,
ESRD or death from any cause, independent of blood
pressure control. In all three treatment arms, blood
pressure at baseline was similar. During the study
follow up, there was no signiﬁcant difference in mean
arterial blood pressure between the amlodipine and
the irbesartan groups, but the control group had a
mean arterial blood pressure 3.3 mmHg higher than
the two active groups. The differences in outcomes
between the active groups cannot, therefore, be
explained by differences in blood pressure control,
but instead may lie in the different mechanisms of
action irbesartan and amlodipine. When the disparity
in blood pressure control between the irbesartan and
placebo groups was adjusted for, the magnitude of
renal beneﬁt afforded by irbesartan did not decrease
signiﬁcantly [3].
One of the main limitations of the study relates
to the fact that the model does not consider
ACE inhibitors, beta-blockers or other angiotensin
2-receptor blockers as treatments for type 2 diabetes
patients with hypertension and nephropathy. In this
analysis we attempted to model the health economic
outcomes of the IDNT and were therefore limited to
the treatment arms included in this particular trial. In
fact, no head-to-head clinical comparisons of irbe-
sartan and ACE inhibitors, beta-blockers or other
angiotensin 2-receptor blockers have been published
in this population at the time of writing, making
direct comparison in the modelling setting difﬁcult.
The cost-effectiveness of angiotensin-receptor
blockers vs ACE inhibitors would be particularly
interesting when appropriate clinical data become
available. Data from a study of ACE inhibitors in
non-diabetic renal patients has indicated that bena-
zepril is cost saving in the US setting [19]. Treatment
of patients with chronic renal insufﬁciency with
benazepril was associated with a total cost saving
of more than USD 4000 ( “3692) per patient over
3 years and USD 23 500 ( “21 690) per patient when
extrapolated to 10 years. The data suggest that
ACE inhibitor treatment has a signiﬁcant impact on
costs for renal patients and highlight the need for
clinical studies comparing antihypertension therapies
in patients with type 2 diabetes, hypertension and
nephropathy to form the basis of an economic
investigation.
In conclusion, this modelling study demonstrated
that the delay in progression to DSC and ESRD by
treating patients with type 2 diabetes, hypertension,
and overt nephropathy with irbesartan led to both
reductions in overall costs and anticipated improve-
ments in life expectancy compared with treatment
with amlodipine or antihypertensive therapy alone.
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